Growth Hormone Secretagogues: Who Should Buy What, and What to Dodge in 2026

Published · Researched 2026-09-21

The category in one paragraph

Growth hormone secretagogues are the peptide scene's workaround for an awkward fact: actual human growth hormone is expensive, prescription-only, and counterfeited relentlessly. Instead of injecting GH itself, these compounds nudge your own pituitary to pulse more of it — either by mimicking GHRH, the "go" signal (CJC-1295, sermorelin, tesamorelin), or by hitting the ghrelin receptor, the "amplify" signal (ipamorelin, the GHRPs, hexarelin). The single most important thing to understand before spending anything: nearly everything here is an unapproved research chemical, and the community's consensus exists in the total absence of long-term safety data. What you're buying into is a well-organized crowd experiment, not medicine.

The picks, by use case

You want the community default — sleep, recovery, general recomposition. The CJC-1295 (no DAC) + Ipamorelin stack, full stop. Across 170 parsed social posts, nothing else comes close: it's the combination in RIPD.FIT's January 2026 "MAXIMUM MUSCLE GAIN PEPTIDE STACK" graphic, in HNR Labs' "two signals combine into one bigger pulse" reel, in Dr. Pat Taylor's September 2026 "THE MOST POPULAR STACK YOU HAVEN'T HEARD OF" carousel, and in Facebook group threads where experienced users debug each other's protocols (documented). Owner reports of better sleep and faster recovery within weeks are remarkably consistent — attributed and anecdotal, but consistent. The trade: daily injections, the infamous "CJC flush" (there is literally a Homelander meme about the panic of your first flush), water retention, and a supply chain so spam-saturated that every comment section doubles as a vendor DM funnel.

You're older, or you want the gentlest on-ramp. Sermorelin — the "Ford Model T," as creator Johnny Papa put it in a February 2026 ranking reel: first on the scene, still runs, slower (documented). It's the only secretagogue here with real clinical history (FDA-approved 1990–2008 as Geref, now compounded), and sleep-focused and older users keep naming it for gentleness. The catch the community is blunt about: it's the weakest of the GHRH options, and most experienced users say stack it with a GHRP rather than run it solo.

You're chasing visceral fat and want credentials. Tesamorelin is the most legitimate compound in the category — FDA-approved since 2010 as Egrifta, with real Phase III data showing roughly 15–17% visceral fat reduction (documented). But the fine print matters: Egrifta runs about $10,500–$11,700 a month (WellRx coupons, September 2026 — documented), so essentially all community use is gray-market — the same molecule with none of the legitimacy. And there's an active, honest debate about whether tesamorelin is genuinely better at fat loss than CJC-1295 or just better studied for it: Josh Holyfield's September 2026 carousel argued the "visceral fat peptide" label is a labeling artifact — same pituitary receptor, same pathway, different trial endpoints (disputed — never tested head-to-head). At gray-market prices the community leans CJC/Ipa; at legit prices nobody sane pays ten grand a month for an off-label experiment.

You won't inject, full stop. MK-677 is the only real answer — but go in with eyes open. It is not a peptide (small-molecule ghrelin mimetic — labeled everywhere because the internet calls it one anyway), it's oral, and it genuinely works for appetite and sleep. It's also the category's worst signal-to-noise ratio: every thread is one part testimonial, one part diabetes warning, one part supplier spam. A Hindi-language testimonial reel shows a user eating ~5,000 calories on day one and sleeping 12 hours (documented); "pharma health coach" Bradley Wilson calls it "stupid as fuck" in an August 2026 reel, citing glucose spikes pushing users toward pre-diabetic range within weeks (documented). If you're glucose-sensitive, this is the one to skip. MK-777, the hyped "next generation" analog, is early-stage with limited human data — efficacy UNVERIFIED, not a pick, just a name to recognize so nobody sells it to you as proven.

You're on a tight budget and want the legacy options. GHRP-6 is the cheapest entry in the class (5 mg at €25.99 from a European vendor, September 2026 — documented) and still gets bulking-phase love for appetite — but ipamorelin displaced it for a reason: no cortisol/prolactin baggage, cleaner pulse. GHRP-2 sits between them: more potent than GHRP-6, less hunger, but fading from 2026 content. Both are community-validated (Tier 1 and Tier 2), both are research chemicals, and neither beats ipamorelin on selectivity — which is exactly why ipamorelin is in the default stack and these aren't.

What are somatropin and macimorelin doing here? Somatropin (real HGH) is the yardstick, not a recommendation. Everything gets measured against direct GH, and the verdict is consistent: more direct, an order of magnitude pricier (~$1,000–$3,000/month cash, community-cited), heavier metabolic and legal baggage, and a black market that's a counterfeit minefield. Secretagogues exist in the price shadow of HGH. Macimorelin is the category's credentialed bookend: the only FDA-approved oral ghrelin agonist — and it's a single diagnostic dose costing $4,403.50 (drugs.com, September 2026 — documented) with zero biohacker adoption. It's in this list to show you what a regulated version looks like, which throws the research-chemical GHRPs' unregulated status into sharp relief.

The traps

CJC-1295 with DAC. The "premium long-acting" framing is the category's biggest marketing-vs-reality gap. Weekly dosing sounds great until you watch the June 2026 Bryan Johnson reel: two doses of CJC-1295 DAC, then he quit — REM sleep down 23%, fasted blood sugar up 20%, insulin resistance up 50%, c-peptide up 53% (his experiment, his biomarkers — documented). The community had already settled this: pulsatile no-DAC is the consensus; DAC's sustained "GH bleed" is exactly what people don't want. It persists as a cheaper-per-month option, not a recommended one.

Hexarelin's "strongest pulse" crown. Mostly vendor-authored lore. The literature documents real desensitization, and it elevates cortisol and prolactin — the two things ipamorelin was chosen to avoid. Short-cycle niche at best, daily driver never.

Alexamorelin. A regulatory ghost: no community, no verified product, and the research found zero genuine product photos. If someone offers it to you, assume mislabeling.

The tesamorelin price trap. Paying pharma prices (~$10k/month) for an off-label body-comp run is the worst value proposition in the category. The credential doesn't survive the price.

The "Peptide Community 101" Facebook group. Flagged in the research as admin-run supplier spam — "verified supplier, join the WhatsApp." Treat any group where the admins sell what the members discuss as a storefront, not a community.

MK-677 hype reels vs. the glucose question. The split is the story: "cheat code for mass" promos from sellers (DiagoFitReal, September 2026 — documented) sit next to diabetes warnings from users watching their fasted glucose climb. Both are real; neither side has long-term data.

The fine print

Nothing here is approved for what the community uses it for — except tesamorelin (for HIV lipodystrophy only) and macimorelin (as a diagnostic). Everything else is a research chemical, and WADA bans the lot under S2.2.4. Quality control is vendor-posted COAs — the community's only trust layer, and a thin one: ≥99% purity claims are vendor claims, not verified. Facebook Marketplace returned zero listings for every peptide query, which tells you the market structure: no used market, no price discovery, no returns — sales happen entirely off-platform, in DMs and Telegram channels, which is exactly where scams live. And the fine print under every community consensus: crowdsourced patterns are not medical guidance, half-lives are UNVERIFIED across the board (no human PK data in the gray market), and the big open questions — whether ipamorelin truly desensitizes (a creator's "45% by week 16" claim is UNVERIFIED), whether tesamorelin really holds IGF-1 stable for 52 weeks without desensitization (creator-cited studies, UNVERIFIED), and the long-term safety of any of this (nonexistent) — are all still open.

The bottom line

If you're buying into this category in 2026, the community has one real answer — CJC-1295 (no DAC) + ipamorelin — plus honest niche picks for the needle-averse (MK-677, with the glucose caveat), the credential-hungry (tesamorelin, gray-market only), and the gentle-entry crowd (sermorelin). Everyone else should wait: if you need pharma-grade certainty, if you're glucose-sensitive, or if a seller is pitching you DAC convenience, hexarelin potency, or a compound nobody's heard of — walk away. The friend-text version: buy the boring consensus stack, or buy nothing.